(nelfinavir mesylate)
The recommended dose is 1250 mg (five 250 mg tablets or two 625 mg tablets) twice daily or 750 mg (three 250 mg tablets) three times daily. VIRACEPT should be taken with a meal. Patients unable to swallow the 250 or 625 mg tablets may dissolve the tablets in a small amount of water [see Dosage and Administration (2.3)].
In children 2 years of age and older, the recommended oral dose of VIRACEPT Oral Powder or 250 mg tablets is 45 to 55 mg/kg twice daily or 25 to 35 mg/kg three times daily. All doses should be taken with a meal. Doses higher than the adult maximum dose of 2500 mg per day have not been studied in children.
For children unable to swallow tablets, VIRACEPT 250 mg tablet(s) may be dissolved in a small amount of water or, VIRACEPT Oral Powder may be administered [see Dosage and Administration (2.3)].
The healthcare provider should assess appropriate formulation and dosage for each patient. Tables 1 and 2 provide dosing guidelines for VIRACEPT tablets and powder based on age and body weight.
| Body weight | Twice daily (BID) 45 – 55 mg/kg ≥2 years | Three times daily (TID) 25 – 35 mg/kg ≥2 years |
|---|---|---|
| Number of tablets (250 mg) | Number of tablets (250 mg) | |
| Kg | ||
10 – 12 | 2 | 1 |
13 – 18 | 3 | 2 |
19 – 20 | 4 | 2 |
≥21 | 4 – 5* | 3† |
| Body weight | Twice daily (BID) 45 – 55 mg/kg | Three times daily (TID) 25 – 35 mg/kg | ||
|---|---|---|---|---|
Kg | Scoops of powder | Teaspoons* of powder | Scoops of powder | Teaspoons* of powder |
9.0 to <10.5 | 10 | 2½ | 6 | 1½ |
10.5 to <12 | 11 | 2¾ | 7 | 1¾ |
12 to <14 | 13 | 3¼ | 8 | 2 |
14 to <16 | 15 | 3¾ | 9 | 2¼ |
16 to <18 | Not recommended† | Not recommended† | 10 | 2½ |
18 to <23 | Not recommended† | Not recommended† | 12 | 3 |
≥23 | Not recommended† | Not recommended† | 15 | 3¾ |
For Patients Unable to Swallow Viracept Tablets
Viracept Oral Powder
VIRACEPT can be used in patients with mild hepatic impairment without any dose adjustment. VIRACEPT should not be used in patients with either moderate or severe hepatic impairment [see Warnings and Precautions (5.2), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].
PATIENT INFORMATION | |
VIRACEPT (VI-ra-cept) | VIRACEPT (VI-ra-cept) |
Important: VIRACEPT can interact with other medicines and cause serious side effects. It is important to know the medicines that should not be taken with VIRACEPT. See the section "Do not take VIRACEPT if you:" | |
What is VIRACEPT? VIRACEPT is a prescription HIV-1 medicine used with other HIV-1 medicines to treat human immunodeficiency virus (HIV-1) infection. HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). It is not known if VIRACEPT is safe and effective in children less than 2 years of age. | |
| |
Before taking VIRACEPT, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Some medicines interact with VIRACEPT. Keep a list of your medicines to show your healthcare provider and pharmacist.
| |
How should I take VIRACEPT?
How should VIRACEPT Oral Powder be prepared?
| |
What are the possible side effects of VIRACEPT? VIRACEPT can cause serious side effects, including:
The most common side effects of VIRACEPT in adults and adolescents (13 years of age and older) include:
The most common side effects of VIRACEPT in children (2 years of age to less than 13 years of age) include:
These are not all the possible side effects of VIRACEPT. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | |
How should I store VIRACEPT?
Keep VIRACEPT and all medicines out of the reach of children. | |
General information about the safe and effective use of VIRACEPT. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VIRACEPT for a condition for which it was not prescribed. Do not give VIRACEPT to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about VIRACEPT that is written for health professionals. | |
What are the ingredients in VIRACEPT? Active ingredient: nelfinavir mesylate Tablet inactive ingredients: calcium silicate, crospovidone, magnesium stearate, hypromellose, and triacetin. In addition, the 250 mg tablet contains FD&C blue #2 powder and the 625 mg tablet contains colloidal silicon dioxide. Oral powder inactive ingredients: microcrystalline cellulose, maltodextrin, dibasic potassium phosphate, crospovidone, hypromellose, aspartame, sucrose palmitate, and natural and artificial flavor. ![]()
| |
This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 10/2023
Additional Resources
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.
Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.
Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for a Pfizer medicine or a vaccine.
The submission will be reviewed during our standard business hours.
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.